|
GB0319028D0
|
|
Pyrazolo-pyrimidine compounds and their use in medicine
|
|
GB0312822D0
|
|
Triazolo-pyrimidine compounds and their use in medicine
|
|
GB0312296D0
|
|
Pyrazolo-pyrimidine compounds and their use in medicine
|
|
GB0308018D0
|
|
Assay method
|
|
GB0307389D0
|
|
Amino pyrazolo[1,5-a]pyrimidine compounds and their use in medicine
|
|
GB0304362D0
|
|
Amino pyrimidine compounds and their use in medicine
|
|
AU2002356301A1
|
|
3,4-diarylpyrazoles and their use in the therapy of cancer
|
|
GB0226194D0
|
|
Pharmaceutical research method
|
|
GB0210439D0
|
|
Antibacterial compounds
|
|
GB0203042D0
|
|
Anthraquinine compounds their preparation and their use in therapy
|
|
GB0203043D0
|
|
Benzimidazloe compounds their preparation and their use in therapy
|
|
GB0202749D0
|
|
Antibacterial agents
|
|
GB0202750D0
|
|
Antibacterial agents
|
|
AU1068602A
|
|
Flavan compounds, their preparation and their use in therapy
|
|
AU7997301A
|
|
Computer-based modelling of ligand/receptor structures
|
|
WO0214545A2
|
|
Method for determining weather a test compound binds to a large rna target
|
|
AU6925901A
|
|
Aryl compounds, their preparation and their use in therapy
|
|
EP1280934A2
|
|
In-silico-screening for docking on sub-domain iiid of hcv-ires
|
|
AU9336701A
|
|
Assay for identification of a test compound
|
|
AU2868601A
|
|
Biaryl compounds, their preparation and their use in therapy
|
